| Name | Title | Contact Details |
|---|
myMatrixx is a full-service pharmacy benefit management (PBM) and ancillary services company focused on workers’ compensation. By combining advanced technology and proactive clinical management throughout the claims process, myMatrixx delivers a Fast, Simple, Effective solution with proven Results. Founded in 2001 by Steven MacDonald, an industry veteran in workers’ compensation, myMatrixx began as a pharmacy benefit manager. Today services include a corporately-owned and operated mail service pharmacy with compounding, ancillary services and DME, and proactive clinical programs. With a focus on workers’ compensation, myMatrixx serves self-insured employers, third party administrators, managed care companies, as well as workers’ compensation and auto insurance companies. From the beginning, we have put the client at the center of everything we do. Their success is our success, and delivering an unimaginably great customer experience is our goal.
The Investor Relations website contains information about Cingulate Incs business for stockholders, potential investors, and financial analysts.
Clyde Chemists is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
UQUIFA is a manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates for the pharmaceutical and animal health industries globally
Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers. Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.